Cipla receives USFDA approval for generic version of Revlimid® (lenalidomide capsules) Kumar Jeetendra | September 7, 2022 Mumbai, India/ New Jersey, United States, September 7, 2022: Cipla Limited (BSE: 500087; NSE: CIPLA EQ) (“Cipla”) announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsule 5 mg, 10 mg, 15 mg and 25 mg from the United States Food and Drug Administration (US FDA). Cipla’s Lenalidomide …
‘Listen to the Future’- Cipla’s digital film reinforces its ESG commitments Kumar Jeetendra | September 14, 2022 Mumbai, India, 14th September: Cipla Limited launched a thought-provoking brand film ‘Listen to the Future’ to reiterate the company’s ESG goals for 2030. To bring alive its ethos of contributing toward a greener environment and sustainable value creation, the film creatively highlights the importance of positive actions through the lens of children. The brand film …
Cipla EU to invest EUR 15 million in ETHRIS, initiating a strategic collaboration Kumar Jeetendra | December 29, 2022 Mumbai, India and Munich, Germany: December 29, 2022: Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as “Cipla” today announced that its wholly owned UK subsidiary, Cipla (EU) Limited (“Cipla EU”) has signed definitive agreements for equity investment of EUR 15 million in Ethris GmbH (“Ethris”), a global leader in delivering mRNAs directly to …
CIPLA launches CIPPOINT, a point-of-care gadget for non-communicable, infectious, and other disorders. Kumar Jeetendra | January 20, 2023 Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced the launch of Cippoint, a point-of-care testing device. This state-of-the-art device offers a wide range of testing parameters including cardiac markers, diabetes, infectious diseases, fertility, thyroid function, inflammation, metabolic markers, and coagulation markers. The device is CE IVD approved – …
Cipla tops BW India’s Most Sustainable Companies Rankings for 2022-23 Kumar Jeetendra | June 30, 2023 Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced that it has been ranked 1st in the Pharmaceuticals & Healthcare Sector and 5th in the Top 50 Most Sustainable Companies at the 3rd edition of BW India’s Most Sustainable Companies Awards 2022-23. This recognition acknowledges Cipla’s efforts in the …
Actor Pharma (PTY) ltd will be acquired by Cipla Medpro South Africa (PTY) ltd (“CIPLA South Africa”) Kumar Jeetendra | September 4, 2023 Cipla South Africa, a 100% owned subsidiary of Cipla Limited(BSE: 500087; NSE: CIPLA EQ; hereafter referred to as “Cipla”) signed a binding term sheet with Actor Holdings (Pty) Limited to acquire 100% of the issued ordinary shares of Actor Pharma (Pty) Limited (“Actor”). This development underpins Cipla’s commitment and investment in its over the counter …
Cipla partners with CSIR-CDRI to advance Ophthalmic Antifungal Treatment Development Kumar Jeetendra | February 19, 2024 Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) announced today that the company has entered into a collaborative research agreement with CSIR-Central Drug Research Institute (CSIR-CDRI), a constituent laboratory of the Council of Scientific and Industrial Research, Government of India, to jointly develop a novel ophthalmic formulation for fungal keratitis. …
Cipla announces additional investment in Achira Kumar Jeetendra | May 16, 2024 Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) announced today that it has signed definitive agreements for further investment of up to INR 26 crore (approx.) in Optionally Convertible Preference Shares of Achira Labs Private Limited, associate company (hereafter referred to as “Achira”) in four tranches, subject to completion of …
Cipla launches CipAir®: AI-Powered App Revolutionizing Asthma Screening in India Kumar Jeetendra | December 18, 2024 Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as “Cipla” today announced the launch of CipAir®️, a mobile application designed to enable timely and convenient first line of screening for asthma in India. This first-of-its-kind technology is clinically validated through a multi-centric pan-India study. It aims to empower people by helping them understand their …
Cipla & Formosa Ink Licensing Deal for Clobetasol Suspension Kumar Jeetendra | March 18, 2025 Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as “Cipla” today announced an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals (6838.TW) for the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007). Under this agreement, Cipla has exclusive rights to market the innovative treatment for post-operative inflammation and pain following ocular surgery across 11 countries …
Cipla Invests in iCaltech to Boost Respiratory Portfolio Kumar Jeetendra | July 22, 2025 Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) announced today that it has signed definitive agreements for investment in Optionally Convertible Preference Shares of iCaltech Innovations Private Limited (hereafter referred to as “iCaltech”), subject to completion of certain conditions. Cipla Invests in iCaltech to Strengthen Respiratory Diagnostics Ecosystem in India …
